Corporate Philosophy
Mission of Noile-Immune Biotech
Recent years have witnessed remarkable strides in the field of tumor immunology. These have brought about the development of drugs and therapies based on novel concepts and have exhibited growing evidence of their efficacy produced in clinical settings, including immune checkpoint inhibitor and gene-modified immune cell therapy. Hence, cancer immunotherapy has been garnering increasing attention worldwide. Meanwhile in Japan, development of new drugs for regenerative medicine, including immune cell therapy, has been accelerated, along with the establishment of the legal environment. This has taken place with enforcement of the Act on Securing Safety of Regenerative Medicine and the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.
Having staff members with a wealth of experience in cutting-edge cancer immunology research both in Japan and the US, Noile-Immune Biotech endeavors to develop the next generation of cancer immunotherapy to deliver new drugs for many patients who are waiting for novel therapies. In this way we aim to contribute to the future of all cancer patients – both adults and children.
The Origin of the company name "Noile"
“No illness”
“Aiming to overcome cancer”
Cancer has been the leading cause of death in Japan since 1981. In recent years, it has been reported that more than 990,000 people have been newly diagnosed with cancer, and over 380,000 people die of cancer annually. The morbidity rate of cancer is still on the rise; the lifetime probability of being diagnosed with cancer is currently 65% for men and 51% for women, meaning 1 in 2 people in Japan will develop cancer. The conventional standard therapies for cancer have comprised of surgery, chemotherapy, and radiotherapy. Today, immunotherapy has been added as one of the important therapies for cancer. Our immune system is capable of monitoring and attacking cancer cells that arise in our body. Cancer immunotherapy holds promise for patients to defeat cancer with their immune system. Noile-Immune Biotech aims to create truly effective cancer immunotherapy through pioneering technology, research, and development, thereby providing the new standard for treatment to cancer patients.
“No immunity, No life”
“We cannot live without immunity”
The immune system of our body has been playing an indispensable role in the survival of human beings throughout history, which is a story of the battle against infectious diseases. With the advancement in molecular biology and tumor immunology, however, the focus of our fight has shifted to cancer. Since 2010, cancer immunotherapies, whose efficacy was proved by large-scale clinical trials, have emerged, leading to the development of immune checkpoint inhibitors. This trend continues; chimeric antigen receptor (CAR)-T cell therapy was granted breakthrough therapy status by the US Food and Drug Administration (FDA) in 2014 and CAR-T cell therapy targeting CD19 was first approved in the US in 2017. Today, the immune response mechanism forms the basic concept underpinning cancer treatment, and cancer immunotherapy is an indispensable element of multidisciplinary cancer treatment.
Noile-Immune Biotech, an academia-originated biotechnology company, has been accelerating its research and development efforts through its partnerships with Yamaguchi University and National Cancer Center Japan (NCC). NCC is Japan’s largest national cancer research center, leading cancer care in Japan. It also serves as an important hub for early-stage clinical trials to initiate global development of new cancer drugs. Noile-Immune Biotech drives the development of new drugs, focusing mainly on CAR-T cell therapy which, among cancer therapies, has been attracting keen attention as the next generation of such treatment.
Noile’s Values: 5C & 1F
Aiming to realize our philosophy, we will act in accordance with six values:
"5C & 1F"
Challenge
Collaboration
Forgiveness
Cutting-edge technology
Compliance
Confidence